

Contents

Volume 1

Preface V

List of Contributors XXXIX

Part A **Dendritic Cell Biology** 1

1 Introduction to Some of the Issues and Mysteries Considered in this Book on Dendritic Cells 3

Ralph M. Steinman

- 1.1 Dendritic Cells as a Distinct Hematopoietic Lineage 3
- 1.1.1 Chapters 1–16, the Life History of Dendritic Cells 3
- 1.1.2 Questions Concerning the Dendritic Cell Lineage 4
- 1.2 Control of Lymphocyte Responses by Dendritic Cells 4
- 1.2.1 Chapters 17–30, Initiation of Immunity 4
- 1.2.2 Questions Concerning Antigen Uptake, Processing and Presentation 5
- 1.2.3 Questions Concerning Dendritic Cell Maturation 5
- 1.3 Dendritic Cells in Disease Pathogenesis 6
- 1.3.1 Chapters 31–51, Dendritic Cells in Infectious and Other Diseases 6
- 1.3.2 Some Questions on the Roles of Dendritic Cells in Diseases 7
- 1.4 Dendritic Cells and the Design of Vaccines and New Therapies 7
- 1.4.1 Chapters 52–55, Dendritic Cells in Immunotherapy 7
- 1.4.2 Dendritic Cells and the Design of Vaccines against Infectious Diseases 8
- References 9

I Dendritic Cell Development 13

2 Bone Marrow Progenitors of Dendritic and Natural Interferon-producing Cells 13

Markus G. Manz

- 2.1 Hematopoietic Stem Cells and Successive Lineage-restricted Early Hematopoietic Progenitor Cells 14

2.2	Proposed Models for Dendritic and Natural Interferon-producing Cell Differentiation	15
2.3	Unexpected Redundancy in Dendritic and Natural Interferon-producing Cell Development from both Lymphoid and Myeloid Restricted Hematopoietic Progenitor Cells	16
2.4	Immediate Dendritic and Natural Interferon-producing Cell Precursors	17
2.5	Proposed “flt3-license” Working Model for Steady-State Dendritic and Natural Interferon-producing Cell Development from Early Hematopoietic Progenitor Cells	18
2.6	Conclusions	20
	Acknowledgement	21
	References	21
3	Growth Factors	27
	<i>Herbert Strobl, Barbara Platzer, Almut Jörgl, Sabine Taschner, Leonhard Heinz and Peter Reisner</i>	
3.1	Introduction	27
3.2	Short Description of Key Cytokines Involved in DC Development	28
3.2.1	Flt3 Ligand (FLT3L, FL)	28
3.2.2	GM-CSF (Granulocyte-macrophage Colony-stimulating Factor)	29
3.2.3	Interleukin 3 (IL-3)	30
3.2.4	Interleukin 4 (IL-4)	30
3.2.5	Interleukin-15 (IL-15)	31
3.2.6	TNF α (Tumor Necrosis Factor-alpha)	31
3.2.7	TGF- β 1 (Transforming Growth Factor Beta-1)	32
3.3	Regulation of <i>in vitro</i> DC Hematopoiesis by Cooperating Cytokine Signals	33
3.3.1	Cytokines in the Induction and Amplification of CD1a ⁺ Myeloid DC Subsets from Hematopoietic Progenitor Cells <i>in vitro</i>	33
3.3.2	Cytokines for Pre-expansion of Myeloid DC Progenitor Cells	35
3.3.3	Cytokine Combinations that Promote Myeloid DC Expansion Reciprocally Inhibit Plasmacytoid DC Development in Suspension Cultures	36
3.3.4	TGF- β 1 and its Essential Co-signals for LC Differentiation from Hematopoietic Progenitor/Stem Cells	39
3.3.5	TGF- β 1 Induces LC Differentiation from Monocyte Intermediates	40
3.3.6	Redundancy among Cytokine Signals Directing LC Differentiation from CD34 ⁺ Hematopoietic Progenitor Cells	41
3.3.7	TGF- β 1-dependent LC Induction by <i>in vivo</i> Occurring Candidate Precursors	41
3.3.8	Cytokines Promoting the Generation of Monocyte-derived DC	42
3.3.9	Evidence for Cellular Heterogeneity of DC Arising from CD34 ⁺ Progenitors or Monocytes	43
3.4	Conclusions	43
	References	44

4	Transcription Factors: Deciphering the Transcription Factor Network of Dendritic Cell Development	53
	<i>Thomas Hieronymus and Martin Zenke</i>	
4.1	Introduction	53
4.2	Ikaros	54
4.3	RelB	55
4.4	PU.1	56
4.5	C/EBPa	57
4.6	Pax5	60
4.7	IRF family	60
4.8	Id2	63
4.9	Runx3	64
4.10	Gfi1	64
4.11	Concluding Remarks	65
	References	66
II	Sentinel Dendritic Cells in Nonlymphoid Organs	73
5	Epidermal Langerhans Cells	73
	<i>Nikolaus Romani, Christoph H. Tripp, Gudrun Ratzinger, Christine Heufler, Franz Koch, Sem Saeland and Patrizia Stoitzner</i>	
5.1	Introduction and Definition	73
5.2	A Short Review of the History of Langerhans Cells	73
5.3	Characterization and Morphology of Langerhans Cells	75
5.4	Entry of Langerhans Cells into the Epidermis in Ontogeny and Adulthood	76
5.4.1	Entry of Langerhans Cells into the Epidermis during Ontogeny	76
5.4.2	Entry and Turnover of Langerhans Cells into the Adult Epidermis under Homeostatic Conditions	77
5.4.3	Entry and Turnover of Langerhans Cells into the Adult Epidermis under Inflammatory Conditions	78
5.5	Lineage of Langerhans Cells	79
5.6	Langerhans Cells in Lymphoid Organs	80
5.7	Langerhans Cells as a Paradigm for Dendritic Cell Function	82
5.8	The Changing of the Paradigm	84
5.9	Can Langerhans Cells Induce Immunity <i>in vivo</i> ?	85
5.10	Can Langerhans Cells maintain Peripheral Tolerance <i>in vivo</i> ?	86
5.11	Can Langerhans Cells be Applied in Immunotherapy?	88
5.12	Recent Methodical Advances Relevant for the Study of Langerhans Cells	89
	Acknowledgements	90
	References	90

6	Characterization of Dendritic Cells and other Antigen-presenting Cells in the Eye 101
	<i>Joan Stein-Streilein</i>
6.1	Introduction 101
6.2	APC in Various Regions of the Eye 103
6.3	DC/APC in the Retina 103
6.4	DC/APC in the Cornea 105
6.5	DC/APC in the Anterior Chamber 105
6.6	Mechanisms of ACAID Induction in the Spleen 107
6.7	The Role of the F4/80 Protein in ACAID 109
6.8	Therapeutic Potential of ACAID APC 110
6.9	Conclusions and Implications 111
	Acknowledgements 111
	Abbreviations 112
	References 112
7	Toll-like Receptors 119
	<i>Hubertus Hochrein and Hermann Wagner</i>
7.1	TLR and their Ligands 119
7.2	TLR Subfamilies 121
7.3	TLR and Dendritic Cell Subsets 122
7.4	TLR Signaling 123
7.5	What Determines the Outcome of the Immune Responses? 124
	References 126
8	C-type Lectins on Dendritic Cells: Antigen Receptors and Modulators of Immune Responses 129
	<i>Yvette van Kooyk and Teunis B.H. Geijtenbeek</i>
8.1	Introduction 129
8.2	DCs and Antigen Recognition Receptors 130
8.3	CLRs as Antigen Receptors for Homeostatic Control 130
8.4	CLRs as Adhesion Receptors 131
8.5	CLRs as Pathogen Receptors 133
8.5.1	HIV-1 as Prototypic Example for Virus-DC-SIGN Interactions 133
8.6	Glycan Modifications and Pathogen Recognition by DCs 134
8.7	CLRs as Signaling Receptors 136
8.8	CLRs and Recognition of Cancer 137
8.9	Concluding Remarks 137
	Abbreviations 138
	Acknowledgements 138
	References 139

9	Scavenger Receptors on Dendritic Cells	141
	<i>Emma J. McKenzie, Subhankar Mukhopadhyay, Siamon Gordon and Luisa Martinez-Pomares</i>	
9.1	Introduction	141
9.2	Structure and Binding Properties of Mammalian Scavenger Receptors	142
9.2.1	Class A Scavenger Receptors	143
9.2.1.1	SR-A I,II and III (SR-A)	143
9.2.1.2	MARCO	144
9.2.1.3	SRCL-I	146
9.2.2	CD36	147
9.2.3	LOX-1	148
9.2.4	SREC-I	149
9.2.5	Other Members of the SR Family	149
9.2.5.1	CD68	149
9.2.5.2	SR-B1, FEEL-1 and FEEL-2	150
9.3	Role of Scavenger Receptors in Dendritic Cell Biology	150
9.3.1	SR and Antigen Internalization for Presentation to the Acquired Immune System	151
9.3.1.1	<i>In vitro</i> Generation of SR Ligands and its Effect in Immunogenicity	151
9.3.1.2	Crosspresentation of Ag Through Uptake of Apoptotic Cells	152
9.3.1.3	Crosspresentation of Ag Acquired through Live Cell Nibbling	153
9.3.1.4	Crosspresentation of Peptide-chaperone Complexes	153
9.3.2	Role of SR in the Modulation of Dendritic Cell Activation	155
9.3.2.1	Role of SR in Modulation of Dendritic Cell Phenotype in Response to Uptake of Apoptotic Cells	155
9.3.2.2	Role of SR in Modulation of Dendritic Cell Phenotype in Response to Uptake of Necrotic Cells	155
9.3.2.3	Cross-talk between SR and Toll-like Receptors	156
9.4	Concluding Remarks	156
	References	157
10	Production of the Long Pentraxin PTX3 by Myeloid Dendritic Cells: Linking Cellular and Humoral Innate Immunity	165
	<i>Paola Allavena, Barbara Bottazzi, Andrea Doni, Luigina Romani, Cecilia Garlanda and Alberto Mantovani</i>	
10.1	Introduction	165
10.2	The Pentraxin Superfamily and the Prototypic Long PTX3: Molecules and Ligands	165
10.3	Myeloid DC as a Major Source of PTX3: Regulation of Production	168
10.4	Blood-circulating Myeloid, but not Plasmacytoid, DC Produce PTX3	169
10.5	Role of PTX3 in Innate Immunity	170

10.6	Function of Antigen Presenting Cells in PTX3-deficient Mice	170
10.7	Conclusion	171
	References	172
11	Gene Profiling of Dendritic cells during Host–Pathogen Interactions	175
	<i>Maria Foti, Francesca Granucci, Mattia Pelizzola, Norman Pavelka, Ottavio Beretta, Caterina Vizzardelli, Matteo Urbano, Ivan Zanoni, Giusy Capuano, Francesca Mingozzi, François Trottein, Toni Aebischer and Paola Ricciardi-Castagnoli</i>	
11.1	Dendritic Cells as Sentinels of the Immune System: Tissue-resident DC and Migratory DC	175
11.2	Study of the Complexity of the Immune System using Gene Profiling	177
11.3	Discovery of IL2 Production by DC using Global Technologies and the NK-DC Interplay	179
11.4	Profiling of Pathogens and Cells of the Innate Response: Mucosal Epithelial Cells, Phagocytic Cells (Neutrophils and Macrophages)	180
11.5	Dendritic Cells and Pathogen Interaction: Dendritic Cells as a Link between Innate and Acquired Immunity	182
11.6	Dendritic Cells as Sensors of Infection	184
11.7	DC Transcriptional Profile Induced by Pathogen Teaches the Dynamic of the Interactions: DC Transcriptome; Core and Specific Responses	185
11.8	DC and <i>Shistosoma Mansoni</i> Specific Signature	186
11.9	DC and <i>Leishmania Mexicana</i> : Molecular Profile of the Interaction	190
11.10	Conclusions	192
	References	192
III	Dendritic Cells in Secondary Lymphoid Organs	199
12	Dendritic Cell Subtypes	199
	<i>Ken Shortman and José A. Villadangos</i>	
12.1	Introduction	199
12.2	DC Surface Antigen Heterogeneity and the Recognition of DC Subtypes	201
12.3	DC Subtypes in Steady-state versus Infected Mice	202
12.4	Extraction and Enrichment of DC from Lymphoid Tissue	203
12.5	Plasmacytoid versus Conventional DC	203
12.6	Spleen DC Subtypes	204
12.7	Lymph Node DC Subtypes	206
12.8	Thymic DC	208
12.9	The Maturation State of Lymphoid Organ DC Subtypes	209
12.10	Generation and Lifespan of DC Subtypes	210

12.11	Human DC Subtypes	211
12.12	Functional Differences between DC Subtypes	212
	References	212
IV	Circulating Dendritic Cells and their Precursors	219
13	pDC: From Plasmacytoid Dendritic Cell Precursors to Professional Type 1 Interferon-producing Cells	219
	<i>Yong-Jun Liu, Holger Kanzler, Yui-Hsi Wang, Yi-Hong Wang, Michel Gilliet, Wei Cao and Tomoki Ito</i>	
13.1	Introduction	219
13.1.1	A Mysterious Cell Type with Plasmacytoid Morphology	219
13.1.2	A Mysterious Cell Type that has the Capacity to Produce Huge Amounts of Type 1 IFNs	221
13.1.3	From pDC to IPC	221
13.1.4	pDCs/IPCs in Mice, Rat, Pig, and Monkey	222
13.2	Isolation and Characterization of pDCs/IPCs	222
13.2.1	Isolation of Human pDCs/IPCs	222
13.2.2	Isolation of Mouse pDCs/IPCs	222
13.2.3	pDC/IPC Morphology	223
13.2.4	Surface Phenotype of pDCs/IPCs	224
13.3	pDC/IPC Development	224
13.4	Localization, Migration, and Lifespan of pDCs/IPCs	227
13.5	Innate Immune Response by pDCs/IPCs	228
13.5.1	pDCs/IPCs Selectively Express Intracellular TLR-7 and TLR-9 that Respectively Recognize Single-Stranded RNA and Double-Stranded DNA	228
13.5.2	pDCs/IPCs Are Professional Type 1 IFN-Producing Cells	229
13.5.3	pDCs/IPCs Rapidly Produce Large Amounts of IFN- α that Is Independent of Positive Feedback of IFN- β Through Type 1 IFN Receptors	230
13.5.4	TLR7/TLR9-mediated IFN- α production by pDCs/IPCs depends on Myd88-IRAK4-TRAF6-IRF-7 complexes	231
13.5.5	Human pDCs/IPCs Have a Limited Ability to Produce IL-12	231
13.5.6	Myeloid DCs Are Specialized in Producing IL-12, but not Type 1 IFNs	233
13.6	Regulation of T-cell-mediated Immune Responses by pDCs/IPCs	233
13.6.1	pDC/IPC Differentiation to Mature DCs through Two Pathways	233
13.6.2	pDC-Derived DCs Induce Th1 by IFN- α but not IL-12	235
13.6.3	pDC-Derived DCs Induce Th2 through OX40L	235
13.6.4	pDC-Derived DCs and their Ability to Prime Naïve versus Memory T Cells	235
13.6.5	pDC-Derived DCs and Presentation of Endogenous and Exogenous Antigens	235
13.6.6	pDCs/IPCs and Cross-priming	236

13.6.7	pDCs/IPCs and Regulatory T Cells	236
13.7	pDCs/IPCs Regulate the Function of Conventional Myeloid DC by Type 1 IFN	237
13.8	Regulation of NK Cell Function by pDCs/IPCs	238
13.9	Regulation of B-cell Function by pDCs/IPCs	239
13.10	pDCs/IPCs and Human Diseases	239
13.10.1	HIV	239
13.10.2	Systemic Lupus Erythematosus (SLE)	239
13.10.3	Cancer	240
13.11	Conclusion	240
	Acknowledgments	241
	References	241
14	Monocyte subsets and their relation to DCs	253
	<i>Brigitte Senechal, Darin Fogg, Gaelle Elain, and Frederic Geissmann</i>	
14.1	Monocytes and the Concept of the “Mononuclear Phagocyte System” (MPS)	254
14.1.1	Blood Monocytes in the Mononuclear Phagocyte System	254
14.1.2	Plasticity of Monocytes as Studied <i>in vitro</i> and its Relevance to DC Differentiation <i>in vivo</i>	256
14.1.3	Contribution of Monocytes to Long-lived Resident Cells in Peripheral Tissues	257
14.1.4	Contribution of Monocytes to Short-lived Bone Marrow-derived Steady State Macrophages and DC	258
14.1.5	Evidence that Monocytes Contribute to Short-lived Migrating Dendritic Cells that Differentiate During Inflammation and Infection	259
14.1.6	Summary of the Respective Contribution of Monocytes to Individual Subsets of the MPS System	260
14.2	Molecular Determinants of Monocyte Differentiation	260
14.3.2	Monocyte Subsets	262
14.3.3	CCR2 ⁺ CX3CR1 ^{low} “Inflammatory” Monocytes	264
14.3.4	The Enigmatic CCR2 ⁻ CX3CR1 ^{high} Monocytes	265
14.3.5	Relationship Between CCR2 ⁺ CX3CR1 ^{low} Monocytes and CCR2 ⁻ CX3CR1 ^{high} Monocytes	266
14.3.6	Additional Subsets of Monocytes?	266
14.4	Migration of Monocytes and Their Recruitment to Tissues	267
14.4.1	Monocyte Entry into the Target Tissues	267
14.4.2	Baseline Extravasation of Monocytes	268
14.4.3	Recruitment of Monocytes During Inflammation and Infection	268
14.5	Concluding remarks	269
	Acknowledgments	270
	References	270

V	Dendritic Cell Migration	279
15	Steady State Migration of Dendritic Cells in Lymph	279
	<i>Gordon MacPherson, Simon Milling, Emma Turnbull and Ulf Yrlid</i>	
15.1	Introduction	279
15.1.1	Dendritic Cells	279
15.1.2	Why Study Lymph Dendritic Cells?	280
15.1.3	Lymphatic Terminology	280
15.1.4	Historical	281
15.2	Dendritic Cells in the Periphery	281
15.2.1	Constitutive Migration of Dendritic Cells from Peripheral Tissues	281
15.2.2	Exit of Dendritic Cells from Peripheral Tissues	282
15.2.3	Entry of Dendritic Cells into Peripheral Lymph	282
15.3	Lymph Dendritic Cells	282
15.3.1	Pseudo-afferent Lymph	282
15.4	Properties of Lymph Dendritic Cells in the Rat	283
15.4.1	Steady-state Output	283
15.4.2	Origin of Afferent Lymph Dendritic Cells	283
15.4.3	Steady-state Rat Lymph Dendritic Cells are “Semi-mature”	284
15.4.4	Subsets of Rat Lymph Dendritic Cells	284
15.4.5	Migratory Fate of Lymph Dendritic Cells	285
15.4.6	Uptake and Transport of Apoptotic Cells by Intestinal Dendritic Cells	286
15.5	Dendritic Cells and B Cells	286
15.6	Dendritic Cells and the Pathogenesis of Transmissible Spongiform Encephalopathies (TSE)	287
15.7	Conclusions	288
	References	288
16	Multiple Pathways to Control DC Migration	295
	<i>Karel Otero, Elena Riboldi, Annalisa Del Prete, Annunciata Vecchi, Fabio Facchetti, Alberto Mantovani and Silvano Sozzani</i>	
16.1	Dendritic Cells as Professional Migratory Cells	295
16.2	Role of Chemokines in the Recruitment of Myeloid and Plasmacytoid Dendritic Cells	296
16.3	Migration of Mature Dendritic Cells to Secondary Lymphoid Organs	298
16.4	Chemotactic Factors for Dendritic Cells: more than Chemokines	301
16.5	Tuning Dendritic Cell Migration by Nonchemotactic Signals	303
16.6	Concluding Remarks	305
	Acknowledgements	305
	References	306

VI	T-cell Activation and Co-stimulation	313
17	Antigen Processing and Presentation: CD1d and NKT cells	313
	<i>Serani L.H. van Dommelen, Dale I. Godfrey and Mark J. Smyth</i>	
17.1	Introduction	313
17.2	CD1d and Antigen Presentation	313
17.2.1	The CD1d Molecule	313
17.2.2	Nature of CD1d and Glycolipid Recognition by TCR	315
17.2.3	Nature of CD1d-expressing APC	316
17.3	CD1d-restricted NKT Cells	318
17.3.1	Defining NKT Cells	318
17.3.2	Tissue Location and NKT Cell Subsets	319
17.4	Nature of the Antigens Presented by CD1d-expressing APC to NKT Cells	319
17.4.1	Self-ligands	320
17.4.2	Naturally-occurring Exogenous Ligands	320
17.4.3	Synthetic Ligands	321
17.5	Effector Functions of NKT Cells	321
17.5.1	Cytokine Secretion and Cytotoxicity of NKT Cells	322
17.5.2	The Initial Cross-talk Between CD1d-expressing APC and NKT Cells	322
17.5.3	Functional Diversity of NKT Cell Responses	323
17.5.4	Modulation of Downstream Immune Responses by α -GalCer-activated Cells	325
17.5.5	Adjuvant-like Effect of NKT Cells on DC Mediated Antigen Presentation	327
17.6	Role of CD1d-restricted NKT Cells in Disease Models	328
17.7	Conclusions	328
	Acknowledgments	328
	References	329
18	The Role of Dendritic Cells in T-cell Activation and Differentiation	343
	<i>Federica Sallusto and Antonio Lanzavecchia</i>	
18.1	Introduction	343
18.2	Requirements for Activation of Naïve T Lymphocytes	343
18.2.1	Co-stimulatory and Inhibitory Pathways	345
18.2.2	Differentiation to Effector T Cells	345
18.3	Dendritic Cell Maturation	346
18.4	T-cell Priming by Dendritic Cells	347
18.4.1	Priming of Th1 and Inflammatory T-cell Responses	348
18.4.2	Priming of Th2 Cells	348
18.4.3	Imprinting Tissue Homing Receptors	349
18.4.4	The Role of Plasmacytoid Dendritic Cells in T-cell Responses	349
18.5	Concluding Remarks	350
	References	350

19 Cytokines Produced by Dendritic Cells 355*David F. Tough*

- 19.1 Introduction 355
- 19.2 DC Cytokine Expression: A Few Caveats 355
- 19.3 Type I Interferon 356
- 19.4 IL-12, IL-23, IL-27 357
- 19.5 IL-18 359
- 19.6 IL-6 360
- 19.7 IL-1 360
- 19.8 TNF- α 362
- 19.9 Concluding Remarks 363
- Acknowledgement 364
- References 364

Volume 2**VII Th1 and Th2 Decision 385****20 The Plasticity of Dendritic Cells Populations in Promoting Th-cell Responses 385***André Boonstra, Giorgio Trinchieri and Anne O'Garra*

- 20.1 Effector Th-cell Populations 385
- 20.2 Factors Inducing the Development of Th1 or Th2 Cells 386
 - 20.2.1 The Strength of DC–Th-cell Interaction 387
 - 20.2.2 Co-stimulators 388
 - 20.2.3 Genetic Background 388
- 20.3 Opposing Concepts: Pre-programmed versus Flexible DC Direct Th-cell Development 388
 - 20.3.1 Mouse Dendritic Cell Populations in Directing Th-cell Development 388
 - 20.3.2 Human Dendritic Cell Populations in Directing Th-cell Development 390
- 20.4 Differential TLR Expression by Distinct Dendritic Cell Populations 392
 - 20.4.1 Modulation of TLR Expression 392
 - 20.5 Modulation of IL-12p70 or IFN- α Production 393
 - 20.6 Factors Responsible for Driving Th2-cell Development 395
 - 20.7 Modulation by Tissue Factors 395
- 20.8 Concluding Remarks 396
- References 397

21 Microbial Instruction of Dendritic Cells 405*Esther C. de Jong, Hermelijn H. Smits, Eddy A. Wierenga and Martien L. Kapsenberg*

- 21.1 Introduction 405
- 21.2 Effector Th1 and Th2 Cells and Regulatory T Cells 405

21.3	Dendritic Cells and Pattern Recognition Receptors	406
21.4	DC-derived Factors that Promote Th1, Th2 or Regulatory T-cell Responses	408
21.4.1	Th1 Cell-promoting Factors	408
21.4.2	Th2 Cell-promoting Factors	410
21.4.3	Regulatory T-cell-promoting Factors	410
21.5	TLR-mediated Activation of DC by Microbes and their Compounds	411
21.5.1	TLR2	411
21.5.2	TLR3	412
21.5.3	TLR4	412
21.5.4	TLR5	413
21.5.5	TLR7/8	413
21.5.6	TLR9	413
21.5.7	TLR10/11	414
21.6	Th1 Cell-promoting DC	414
21.7	Th2 Cell-promoting DC	415
21.8	Regulatory T-cell-promoting DC	415
21.9	Indirect Priming of DC	416
21.10	Concluding Remarks	417
	References	417

VIII CTL Priming and Crosspresentation 427

22	Crossprocessing and Crosspresentation	427
	<i>Mojca Škoberne and Nina Bhardwaj</i>	
22.1	Introduction	427
22.2	Acquisition of Antigens for Crosspresentation	428
22.2.1	Cells that Crosspresent	428
22.2.2	Sources of Antigens and Receptors involved in Crosspresentation	430
22.2.2.1	Apoptotic Cells	430
22.2.2.2	Necrotic Cells	432
22.2.2.3	Heat-shock Proteins	432
22.2.2.4	Immune Complexes	433
22.2.2.5	Nibbling from Live Cells	434
22.2.2.6	Exosomes	434
22.2.2.7	TLR and MyD88 involvement in Crosspresentation	435
22.3	Mechanisms of Crossprocessing and Crosspresentation	436
22.3.1	Entry into the Classical Endocytic Pathway	436
22.3.2	Phagosome–endosome Compartment	438
22.3.3	A Special Mechanism for Soluble Antigens?	439
22.3.4	Tap Dependence and Endocytic Exchange Mechanism (Vacuolar Pathway)	440
22.3.5	Transfer of Peptides via Gap Junctions	441

22.4	Physiological Relevance of Crosspresentation	442
	Acknowledgements	442
	References	443
23	A Systems Biologist's View of Dendritic Cell–Cytotoxic T Lymphocyte Interaction	455
	<i>Burkhard Ludewig and Gennady Bocharov</i>	
23.1	Introduction	455
23.2	Deciphering the Systems Biologist's Approach	456
23.2.1	Modularity and Protocols	457
23.2.2	Feedback Control	458
23.2.3	Redundancy	460
23.2.4	Structural Stability	461
23.3	From Systems Biology to DC–CTL Immunobiology	461
23.3.1	Dynamics of CTL Activation and Differentiation	462
23.3.2	Multiple Levels of Positive and Negative Feedback Control	463
23.3.2.1	Managing DC Recruitment and Antigen Translocation	464
23.3.2.2	Elimination of DCs by Effector CTL	464
23.3.2.3	Rapid Amplification of Signals through Molecular “Ping–Pong” Interactions	464
23.3.2.4	Limiting the CTL “Overshoot” through Feedforward Control	465
23.3.3	DC Subsets Provide Redundant Activating Signals	466
23.3.4	Tuning of Dendritic Cell Activation	468
23.3.4.1	Excitement through Pattern Recognition	468
23.3.4.2	DC Tuning and Tolerance to Self-antigens	469
23.4	Conclusions	470
	Acknowledgments	470
	References	471
IX	Dendritic Cells Cross-talk with Other Cell Types	481
24	Dendritic Cells and Natural Killer Cells	481
	<i>Magali Terme and Laurence Zitvogel</i>	
24.1	Introduction on NK Cells	481
24.2	Activation of NK Cells by DC	482
24.2.1	NK-cell Activation and DC Subsets	483
24.2.2	Molecular Mechanisms of the DC-mediated NK-cell Activation	483
24.3	Reciprocal Interaction of DC and NK Cells	484
24.3.1	DC Maturation Induced by NK Cells	485
24.3.2	Lysis of DC by Activated NK Cells	485
24.4	Where do DC Meet NK Cells?	486
24.4.1	In Lymph Nodes	486
24.4.2	In the Periphery	487
24.5	DC/NK Cross-talk and T Lymphocytes	487

24.5.1	Bridging Innate and Adaptive Immunity	487
24.5.2	Modulation of the DC/NK-cell Cross-talk by CD4 ⁺ CD25 ⁺ Regulatory T Cells and Conventional T Cells	489
24.6	The DC/NK-cell Cross-talk in Physiopathology	490
24.6.1	In Infectious Diseases	490
24.6.1.1	Viral Infections	490
24.6.1.2	Bacterial Infections	491
24.6.2	In Cancer	491
24.7	Concluding Remarks	493
	References	494
25	Intercellular Communication via Protein Transfer	499
	<i>Marca H.M. Wauben</i>	
25.1	What are Exosomes, and Where do they Come From?	499
25.2	Which Cells are Targets for Exosomes, and how do Exosomes Interact with these Cells?	500
25.3	What is the Consequence of Exosome Binding or Uptake for the Target Cell?	501
25.4	What is the Physiological Role of Exosomes in the Immune System?	502
25.5	Cell–Cell Contact-dependent Transfer of Membrane Proteins	504
25.6	How are Membrane Proteins Transferred Between Immune Cells, and What is their Fate?	506
25.7	What is the Physiological Role of Membrane Protein Swapping in the Immune System?	508
25.8	Concluding Remarks	509
	Abbreviations	509
	References	510
X	Tolerogenic Dendritic Cells	517
26	Differentiation Stages and Subsets of Tolerogenic Dendritic Cells	517
	<i>Manfred B. Lutz</i>	
26.1	Introductory Remarks	517
26.2	Mechanisms of T-cell Tolerance Induction	518
26.2.1	Ignorance	519
26.2.2	Anergy	519
26.2.3	Deletion	519
26.2.4	Immune Deviation	520
26.2.5	The Concept of “Immune Balance”	520
26.2.6	Regulation/suppression	521
26.2.7	Combinations	521
26.3	Tolerogenic DC Subsets <i>in vivo</i>	522
26.3.1	Thymic DC	522

26.3.2	DC in Lymph Nodes and Spleen	523
26.3.3	Migratory DC from Peripheral Organs	523
26.3.4	Plasmacytoid DC	524
26.4	DC Precursors	524
26.5	Immature DC	525
26.5.1	Tissue Resident DC	525
26.5.2	Induction of T-cell Anergy by Immature DC	525
26.5.3	Maturation Inhibitors	526
26.5.4	Maturation Resistance	526
26.6	Semi-mature DC	528
26.6.1	Steady-state Migratory DC	530
26.7	Fully Mature DC	531
	Acknowledgements	531
	Abbreviations	531
	References	532
27	Dendritic Cell Manipulation with Biological and Pharmacological Agents to Induce Regulatory T Cells	545
	<i>Luciano Adorini and Giuseppe Penna</i>	
27.1	Introduction	545
27.2	Mechanisms Promoting Tolerogenic Dendritic Cells	546
27.2.1	Indoleamine 2,3-dioxygenase	547
27.2.2	Immunoglobulin-like Transcripts	547
27.3	Induction of Tolerogenic Dendritic Cells	548
27.3.1	Biological Agents Promoting Tolerogenic Dendritic Cells	549
27.3.1.1	IL-10	549
27.3.1.2	TGF- β	550
27.3.1.3	TNF- α	550
27.3.1.4	G-CSF	551
27.3.2	Pharmacological Agents Promoting Tolerogenic Dendritic Cells	551
27.4	Induction of Tolerogenic Dendritic Cells by VDR Agonists	553
27.4.1	Tolerogenic Dendritic Cells Induced by VDR Agonists lead to enhancement of regulatory T cells	555
27.4.2	Upregulation of Inhibitory Receptor Expression in Dendritic Cells by VDR agonists	556
27.4.3	Modulation of Chemokine Production by VDR Agonists can affect Recruitment of Effector T cells and CD4 ⁺ CD25 ⁺ T cells to Inflammatory Sites	557
27.5	Common Features of Agents Leading to Induction of Tolerogenic DCs	558
27.6	Conclusions	559
	References	560

- 28 Surface Molecules Involved in the Induction of Tolerance by Dendritic Cells** 569
Laura C. Bonifaz
- 28.1 Introduction 569
- 28.2 Dendritic Cells and Central Tolerance 570
- 28.3 Dendritic Cells and Peripheral Tolerance 570
- 28.4 C-type Lectin Receptors 571
- 28.4.1 Advantages of DEC-205 as an Endocytic Receptor for Antigen Presentation 572
- 28.4.2 DEC-205: an Endocytic Receptor that Preserves the Steady State in the DC after the Capture of the Antigen 573
- 28.5 Induction of Peripheral Tolerance by Resting Dendritic Cells 573
- 28.5.1 The Same Dendritic Cells Could Operate in the Induction of Immunity 574
- 28.5.2 The Induction of Tolerance by Steady-state Dendritic Cells Promotes Avoidance of the Induction of Autoimmunity 574
- 28.5.3 Surface Molecules are Involved in Peripheral Tolerance Induction by Resting Dendritic Cells through DEC-205 575
- 28.5.4 Additional Evidence Supports the Role of Resting DC in the Induction of Peripheral Tolerance 575
- 28.6 Surface Molecules Involved in the Induction of Peripheral Tolerance 576
- 28.7 Other Receptors Involved in the Induction of Tolerance that can Preserve the Resting of DC or Induce Negative Signaling 577
- 28.7.1 Integrins 577
- 28.7.2 Fc Receptors 578
- 28.7.3 Suppressor and Regulatory T Cells 578
- 28.8 Notch Ligands as Surface Molecules Involved in the Induction of Regulatory T Cells 579
- 28.9 ILT-3 and ILT-4: Two Inhibitory Molecules Involved in Tolerance Induction 580
- 28.10 Special DC for Tolerance? 581
- 28.11 Regulatory–tolerogenic DC 582
- 28.12 Concluding Remarks 582
- Acknowledgments 583
- References 583
- 29 Interaction Between Dendritic Cells and Apoptotic Cells** 591
Adriana T. Larregina and Adrian E. Morelli
- 29.1 Introduction 591
- 29.2 Dendritic Cells Phagocytose and Process Apoptotic Cells 592
- 29.3 The Phagocytic Synapse 593
- 29.3.1 Externalized Phosphatidylserine (PS) and Receptors for PS 595
- 29.3.2 Thrombospondin-1 (TSP-1), CD36 and the Integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ 596

- 29.3.3 Complement Factors and Complement Receptors (CR) 596
- 29.3.4 Pentraxins 598
- 29.3.5 Milk-fat Globule Protein Epidermal Growth Factor 8 (MFG-E8)/lactadherin 598
- 29.3.6 Other Apoptotic Cell Recognition Signals 599
- 29.4 Redundant Receptors and Backup Mechanisms for Apoptotic Cell Clearance 600
- 29.5 Regulatory Effects of Early Apoptotic Cells on Dendritic Cells 600
- 29.6 Molecular Mechanisms of the Interaction between Dendritic Cells and Apoptotic Cells 602
- 29.7 Dendritic Cells, Apoptotic Cells and Peripheral Tolerance 603
- 29.8 The Potential Therapeutical Use of Apoptotic Cells for Peripheral Tolerance 605
- 29.9 Pathogens and Apoptotic Cell-like Mimicry 607
- 29.10 Dead Cells and the Delicate Balance between Immunity and Tolerance 608
- 29.11 Concluding Remarks 610
Acknowledgements 610
References 611

30 Pharmacologically Modified Dendritic Cells: A Route to

Tolerance-associated Genes 619

Kathleen F. Nolan, Stephen F. Yates, Alison M. Paterson, Paul J. Fairchild and Herman Waldmann

- 30.1 Dendritic Cells, Maturation and Tolerance 619
- 30.2 Gene Profiling 622
 - 30.2.1 Gene Profiling Technologies 623
 - 30.2.2 Serial Analysis of Gene Expression (SAGE) 624
 - 30.2.2.1 SAGE Methodology 625
 - 30.2.2.2 Handling Raw SAGE Data 627
 - 30.2.3 Accumulation of a Comparative SAGE Resource for Identifying Tolerance-associated Genes 628
 - 30.2.3.1 Relationship of Modulated DC Populations based on Gene Expression Patterns 631
 - 30.2.3.2 Elucidation of “Signatures” of Genes Associated with Tolerance 632
 - 30.2.3.3 Identification of Novel Genes 634
 - 30.2.3.4 AQ4 SAGE Library Comparisons Provide Insights to Biological Mechanism 634
- 30.3 Downstream Assessment of Tolerance Associated Candidate Genes 636
 - 30.3.1 Simultaneous Assessment of Multiple Candidate Gene Expression Levels using a Custom “ImmunoChip” 636
 - 30.3.2 Assessing the Functional Relevance of Tolerance Candidates by Genetic Manipulation of DCs 637

30.3.3	Assessing the Functional Impact of Candidates in an <i>in vivo</i> Tolerance Model	638
30.4	Downstream Clinical Relevance	638
	References	639
Part B	Dendritic Cells in Disease	649
XI	Parasites	651
31	Malaria	651
	<i>Britta C. Urban and Francis M. Ndungu</i>	
31.1	Introduction to Malaria	651
31.2	Antigenic Variation	652
31.3	Animal Models for Malaria	653
31.4	Acquired Immunity to Malaria	653
31.4.1	Immune Response to Liver Stages	654
31.4.2	Cellular Immunity to the Erythrocytic Stage	654
31.4.3	Humoral Immunity to the Erythrocytic Stage	655
31.5	Immune Recognition of iRBC	656
31.5.1	Toll-like Receptors	656
31.5.2	CD36	657
31.5.3	Other Scavenger Receptors	658
31.5.4	Complement and Fc Receptors	658
31.6	Dendritic Cells in Malaria	658
31.6.1	DCs in Human Malaria	658
31.6.2	DCs in Rodent Malaria	659
31.7	Synopsis	660
	Acknowledgments	662
	References	663
32	Dendritic Cells in Leishmaniasis: Regulators of Immunity and Tools for New Immune Intervention Strategies	669
	<i>Heidrun Moll</i>	
32.1	Introduction	669
32.2	Mechanisms Mediating Resistance or Susceptibility to <i>Leishmaniasis</i>	670
32.2.1	The Role of T Helper Cell Subsets	671
32.2.2	The Role of Regulatory T Cells	672
32.3	Dendritic Cell Interaction with <i>Leishmania</i> Parasites	673
32.3.1	Parasite Uptake by Dendritic Cells	673
32.3.2	Subcellular Location of <i>Leishmania</i> Parasites in Dendritic Cells	674
32.3.3	Dendritic Cell Subsets Involved in the Uptake of <i>Leishmania</i>	675
32.3.4	Dendritic Cells in <i>Leishmania</i> -infected Tissues	676
32.4	Dendritic Cell Migration and Induction of a <i>Leishmania</i> -specific Immune Response	676

- 32.4.1 The Role of Chemokines and Chemokine Receptors Expressed by Dendritic Cells 677
- 32.4.2 Transport and Presentation of *L. major* Antigen by Dendritic Cells 678
- 32.4.3 Parasite Persistence in Immune Hosts 680
- 32.5 Regulation of the Leishmania-specific Immune Response by Dendritic Cells 680
- 32.5.1 The Role of IL-12 Production by Dendritic Cells 681
- 32.5.2 Other Parameters that may Govern the Polarization of T Helper Cells 682
- 32.6 Parasite Evasion of Dendritic Cell Function 683
- 32.7 Dendritic Cells as Tools for Novel Immune Intervention Strategies Against *Leishmaniasis* 685
- 32.7.1 Dendritic Cell-based Vaccination and Immunotherapy 685
- 32.7.2 Parameters Determining the Efficacy of Dendritic Cell-based Immune Intervention Strategies 686
- 32.8 Conclusions and Perspectives 687
- References 688

33 Sentinel and Regulatory Functions of Dendritic Cells in the Immune Response to *Toxoplasma gondii* 693

Alan Sher, Felix Yarovinsky, Romina Goldszmid, Julio Aliberti and Dragana Jankovic

- 33.1 Introduction 693
- 33.2 Activation of DC by *T. gondii* 694
- 33.2.1 Responsive DC Subpopulations 694
- 33.2.2 Host Receptors and Parasite Ligands Involved in Triggering of Murine DC 696
- 33.2.3 Activation of Human DC 698
- 33.3 Regulation of DC Activity 699
- 33.4 Role of DC in *T. gondii*-induced Immune Polarization 700
- 33.5 Mechanisms of Antigen Presentation to T Cells 702
- 33.6 Towards an Understanding of DC Function *in vivo* 703
- Acknowledgements 704
- References 705

34 Schistosoma 709

Andrew S. MacDonald and Edward J. Pearce

- 34.1 Introduction 709
- 34.2 DC Response to Schistosome Ag 710
- 34.3 Th2 Induction by DC in Response to Schistosome Ag 714
- 34.4 DC During Schistosome Infection 717
- 34.5 Discussion 718
- Acknowledgements 719
- References 719

XII	Bacteria	723
35	Dendritic Cells and Immunity to Salmonella	723
	<i>Mary Jo Wick</i>	
35.1	Introduction	723
35.2	Dendritic Cell Subsets, Short and Sweet	724
35.3	Dendritic Cells and Salmonella: Lessons from <i>in vitro</i> Studies	724
35.3.1	Bacterial Uptake and the Fate of Internalized Bacteria	724
35.3.2	Presentation of Salmonella Antigens by Dendritic Cells	727
35.3.2.1	Processing of Salmonella for Direct Presentation on MHC-II by Infected Dendritic Cells	727
35.3.2.2	Processing of Salmonella for Direct Presentation on MHC-I by Infected Dendritic Cells	727
35.3.2.3	Modulating of Antigen Presentation by Salmonella	728
35.3.2.4	Waste not, Want not: Dendritic Cells as Bystander Antigen-presenting Cells	729
35.4	Time to go to Work: Salmonella-induced Dendritic Cell Maturation	730
35.5	Murine Infection Models to Study Dendritic Cell Interaction with Salmonella <i>in vivo</i>	733
35.5.1	Salmonella Infection and Penetration of the Intestinal Epithelium	733
35.5.2	Dendritic Cell Take-up Salmonella <i>in vivo</i>	734
35.5.3	Getting the Game Started: Dendritic Cells Initiate Adaptive Immunity to Salmonella	734
35.5.3.1	Salmonella-induced Dendritic Cell Maturation During Infection	734
35.5.3.2	Presentation of Salmonella Antigens by Dendritic Cells <i>in vivo</i>	736
35.6	Concluding Remarks	737
	Acknowledgements	737
	References	738
36	Dendritic Cells in Tuberculosis	745
	<i>Ulrich E. Schaible and Florian Winau</i>	
36.1	Introduction	745
36.2	Tuberculosis	745
36.3	Mycobacteria are Intracellular Pathogens	747
36.4	Dendritic Cells Present Antigens in Tuberculosis	749
36.5	Dendritic Cells are Regulatory Cells in Tuberculosis	752
36.6	Dendritic Cells and Cross-Priming	753
36.7	Mycobacteria Interfere with Antigen Presenting Cell Function	755
36.8	Conclusion	756
	Acknowledgement	756
	References	756

- 37 Dendritic Cell–Epithelial Cell Interactions in Response to Intestinal Bacteria 759**
Maria Rescigno
- 37.1 The Intestinal Epithelium and the Gut-associated Lymphoid Tissue (GALT) 759
- 37.2 Antigen Uptake in the Gut and DC Populations 760
- 37.3 Cross-talk between Bacteria and Epithelial Cells 762
- 37.4 Unique Functions of Mucosal DCs 763
- 37.5 Intestinal Immune Homeostasis is Regulated by the Cross-talk between ECs and DCs 764
- 37.6 Cross-talk between ECs and DCs in Bacterial Handling 766
- 37.7 Conclusions 767
 References 767

Volume 3

XIII Viruses 773

- 38 Sleeping with the Enemy: The Insidious Relationship between Dendritic Cells and Immunodeficiency Viruses 773**
L. Vachot, S.G. Turville, S. Trapp, S. Peretti, G. Morrow, I. Frank and M. Pope
- 38.1 Introduction 773
- 38.1.1 The Global AIDS Epidemic 773
- 38.1.2 Overview of Dendritic Cell Involvement in the Onset and Spread of HIV Infection 774
- 38.1.3 *In vivo* Evidence for DC Involvement in HIV Infection 776
- 38.1.3.1 Macaque Studies on Mucosal DCs and Infection 776
- 38.1.3.2 Changes in DC Biology in Immunodeficiency Virus Infection 777
- 38.2 Consequences of DC–HIV Interplay 778
- 38.2.1 HIV-binding Receptors Expressed by DCs 778
- 38.2.2 HIV Infection of DCs 780
- 38.2.3 Internalization of HIV Particles by DCs 782
- 38.3 DC-to-T-cell Transmission of Infectious Virus 783
- 38.3.1 Immunodeficiency Virus Replication in the DC–T Cell Milieu 783
- 38.3.2 Virus Movement across DC–T-cell Synapses 784
- 38.3.3 Two Phases of Virus Spread from DCs to T Cells 786
- 38.4 Inhibiting DC-driven Infection 788
- 38.4.1 Preventing direct HIV Interactions with DCs and DC–T-Cell Mixtures 788
- 38.4.2 DC-mediated HIV Transmission to T cells 789
- 38.5 Functional Modification of DCs by HIV Favors Infection over Immunity 790
- 38.5.1 Viral Factors Modify moDCs 790

- 38.5.2 Effects of Virus on Circulating DC Subsets 791
- 38.5.3 Virus-carrying Immature DCs Activate Substandard Virus-specific T-cell Responses 792
- 38.6 Implications for Vaccine and Microbicide Strategies 793
 - 38.6.1 Blocking Mucosal Infection 793
 - 38.6.2 Using DCs to Boost Immunity 794
 - 38.6.2.1 DC-induced Primary Responses for Preventative HIV Vaccines 795
 - 38.6.2.2 DC-based Therapeutic Control of Existing Immunodeficiency Virus Infection 796
- 38.7 Summary and Future Perspectives 797
 - Acknowledgements 797
 - References 797

- 39 Cytomegalovirus Infection of Dendritic Cells 813**
Brigitte Sénéchal and James W. Young
 - 39.1 Introduction 813
 - 39.2 HCMV Induces Immunosuppression 813
 - 39.3 A Role for Dendritic Cells in the Pathology of CMV Infection 814
 - 39.4 The Myeloid Lineage and Monocytes are Major Sites of HCMV Latency 814
 - 39.5 Human Dendritic Cells are a Potential Target for HCMV 815
 - 39.6 *In vitro* Evidence for HCMV Entry and Replication into Dendritic Cells 816
 - 39.7 HCMV Impairs the Function of Immature Dendritic Cells 817
 - 39.8 HCMV Impairs the Function of Mature Dendritic Cells 818
 - 39.9 Langerhans-type Dendritic Cells are also Permissive to HCMV 819
 - 39.10 Importance of Viral IL-10 in HCMV-induced Immunosuppression 820
 - 39.11 CMV Infection of Dendritic Cells in the Mouse Model 820
 - 39.12 Conclusion 822
 - Acknowledgements 823
 - References 823

- 40 Interactions of Hemorrhagic Fever Viruses with Dendritic Cells 829**
Stefan Pöhlmann
 - 40.1 Introduction 829
 - 40.2 Filoviruses 830
 - 40.2.1 Pathology and Epidemiology 830
 - 40.2.2 Replication 831
 - 40.2.3 Tropism 832
 - 40.2.4 Dendritic Cells are Major Targets of Ebolavirus 832
 - 40.2.5 Filovirus Infection causes Aberrant Dendritic Cell Maturation 833
 - 40.2.6 Filoviral Protein(s) Suppress Dendritic Cell Maturation 834
 - 40.3 Dengue Virus (DEN) 835
 - 40.3.1 Epidemiology and Pathology 835

- 40.3.2 Replication 836
- 40.3.3 Dengue Hemorrhagic Fever 836
- 40.3.4 Skin Dendritic Cells are Early Targets of Dengue Virus 837
- 40.3.5 Differential Effects of Dengue Virus on Infected and Bystander Dendritic Cells 837
- 40.4 Lassa Virus (LV) 839
- 40.5 Hantavirus (HTV) 840
- 40.6 Filoviruses and DEN Engage DC-SIGN, a Lectin Expressed on DCs 841
- 40.6.1 DC-SIGN – a Portal for Pathogens 841
- 40.6.2 Does DC-SIGN Promote Filovirus Infection *in vivo*? 842
- 40.6.3 DC-SIGNR – a DC-SIGN-related Attachment Factor that might Concentrate Filoviruses in Liver and Lymph Nodes 844
- 40.6.4 Dengue Virus Targets Dendritic Cells via DC-SIGN 844
- 40.7 Conclusions 845
- Acknowledgements 846
- Abbreviations 846
- References 847

- 41 Dendritic Cells in Measles Virus Pathogenesis 855**
Marion Abt, Nora Mueller and Sibylle Schneider-Schaulies
- 41.1 General Introduction 855
- 41.2 The Virus: Structure and Genotypes 856
- 41.3 The Role of Entry Receptors in Measles Virus Pathogenesis 857
- 41.4 Dendritic Cells in Measles Virus Pathogenesis 859
- 41.4.1 Measles Virus Interaction with Receptors on Dendritic Cells and Functional Consequences 860
- 41.4.1.1 Interaction with Surface Receptors 860
- 41.4.1.2 Functional Consequences of Measles Virus Surface Interaction with Dendritic Cells 861
- 41.4.2 Impact of Measles Virus on Dendritic Cell Viability and Maturation 862
- 41.4.3 Impact of Measles Virus on External Maturation/Stimulation Signals in Dendritic Cells 863
- 41.4.4 Impact of Dendritic Cells Measles Virus Infection on T-cell Viability, Activation and Expansion 864
- 41.5 Conclusions and Perspectives 865
- Acknowledgment 867
- Abbreviations 868
- References 868

- 42 Dendritic Cells and Herpes Simplex Virus Type 1 875**
Alexander T. Prechtel and Alexander Steinkasserer
- 42.1 The Herpes Simplex Virus Type 1 875
- 42.1.1 A Well-known Plaque for Centuries 875

- 42.1.2 The Role of Viral Immediate-early Proteins During the Conquest of the Cell 875
 - 42.1.3 The Course of Herpes Simplex Virus Type 1 Infection and Replication 878
 - 42.2 Herpes Simplex Virus meets Dendritic Cells 879
 - 42.2.1 The Way into Dendritic Cells 879
 - 42.2.1.1 Receptors and Ligands for Cell Entry 879
 - 42.2.1.2 Infection of Different Dendritic Cell Populations by Herpes Simplex Virus Type 1 880
 - 42.2.2 Interference with Typical Functions of Dendritic Cells 881
 - 42.2.2.1 Interference with Dendritic Cell Maturation 881
 - 42.2.2.2 Interference with Dendritic Cell Migration 882
 - 42.2.2.3 Interference with Dendritic-cell-mediated T-cell Stimulation 884
 - 42.3 The Cell Surface Molecule CD83 885
 - 42.3.1 Characteristics of CD83 885
 - 42.3.2 Modulation of Dendritic Cell Function by Interference with CD83 mRNA Processing 886
 - 42.3.3 The Soluble Extracellular Domain of CD83 and its Influence on T-cell Proliferation 887
 - 42.3.4 *The Function of Membrane-bound CD83* 887
 - 42.3.5 Influence of CD83 on the T-cell Development in the Thymus 888
 - Abbreviations 889
 - References 889
- 43 Epstein–Barr Virus 897**
Christian Münz
- 43.1 The Epstein–Barr Virus (EBV) 897
 - 43.2 Immune Control of Epstein–Barr Virus 898
 - 43.3 Stimulation of Lymphocyte Compartments Relevant to Epstein–Barr Virus Immune Control *in vitro* 899
 - 43.3.1 Tonsillar Natural Killer Cell Activation by Dendritic Cells and its Possible Role in Epstein–Barr Virus Infection 899
 - 43.3.2 Initiation of Epstein–Barr Virus-specific T-cell Immunity by Dendritic Cells 900
 - 43.4 Evidence for Priming of Epstein–Barr Virus Immune Control by Dendritic Cells *in vivo* 901
 - 43.4.1 Strong Th1 Polarization of CD4⁺ T-cell Responses to the Nuclear Antigen 1 of Epstein–Barr Virus (EBNA1) 901
 - 43.4.2 Priming of Epstein–Barr Virus-specific Responses by Crosspresentation via Dendritic Cells Leads to Heterogeneous Affinity of T-cell Responses 903
 - 43.5 Detection of Epstein–Barr Virus Infection by the Immune System 903

- 43.6 Immunotherapeutic use of Dendritic Cells against Epstein–Barr Virus 904
- 43.7 Summary 905
- References 906

XIV Fungi 915

44 Dendritic Cells in Immunity and Vaccination against Fungi 915

Luigina Romani and Paolo Puccetti

- 44.1 Introduction 915
- 44.2 Immunity to Fungi 916
- 44.3 Dendritic Cells at the Host/Fungi Interface 917
- 44.3.1 Fungal Recognition by Dendritic Cells and Receptor Cooperativity 918
- 44.3.2 Dendritic Cell Activation 921
- 44.3.3 Dendritic Cell Conditioning 923
- 44.3.3.1 Opsonins 923
- 44.3.3.2 Tryptophan Metabolic Pathway 924
- 44.3.3.3 T-cell Ligands 925
- 44.3.3.4 Other Cells 925
- 44.4 Dendritic Cells Translate Fungus-associated Information to Th1, Th2 and Treg Cells 926
- 44.5 Exploiting Dendritic Cells as Fungal Vaccines 927
- 44.6 Conclusions and Perspectives 928
- Acknowledgements 929
- Abbreviations 929
- References 930

XV Autoimmunity 935

45 Dendritic Cells in Autoimmune Diseases 935

Alexis Mathian, Sophie Koutouzov, Virginia Pascual, A. Karolina Palucka and Jacques Banchereau

- 45.1 Introduction 935
- 45.2 Dendritic Cells 936
- 45.3 Dendritic Cells and Tolerance 936
- 45.3.1 Central Tolerance 936
- 45.3.2 Dendritic Cells and the Control of Peripheral Tolerance 938
- 45.4 Dendritic Cell Activation and the Priming of Autoimmune Diseases 939
- 45.4.1 Autoimmunity through Bystander Activation of Dendritic Cells 940
- 45.4.1.1 Systemic Lupus Erythematosus as an IFN- α Driven Disease 941
- 45.4.2 Defective Downregulation of Activated Dendritic Cells 942
- 45.4.3 The Rise of “Autoimmune-prone” Dendritic Cell Subsets 942

- 45.5 Dendritic Cells Migrate into Inflammatory Sites and Maintain a Vicious Circle 945
- 45.6 Dendritic Cells: Failure to Maintain Peripheral Tolerance 946
- 45.7 A Special Role for Plasmacytoid Dendritic Cells in Systemic *Lupus Erythematosus* 947
- 45.7.1 Plasmacytoid Dendritic Cells as the Main Producer of Type I IFN in Systemic *Lupus Erythematosus* 948
- 45.7.2 Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation 948
- 45.8 Dendritic Cells Fail to Delete Developing Autoreactive T Cells 949
- 45.9 Autoimmunity Through Cytokine-induced Dendritic Cell Activation 949
- 45.10 Different Cytokines Generate Different Dendritic Cells that may lead to Different Autoimmune Syndromes 950
- 45.11 Concluding Remarks 951
 - Acknowledgements 951
 - References 952

XVI Transplantation 967

46 Role of Dendritic Cells in Graft Rejection and Graft-versus-host Disease 967

Véronique Flamand and Michel Goldman

- 46.1 Alloantigen Presentation in Organ Transplantation 967
 - 46.1.1 Pathways of Alloantigen Recognition 967
 - 46.1.1.1 The Direct and Indirect Pathways 967
 - 46.1.1.2 The Semi-direct Pathway 969
 - 46.1.2 Sites of Alloantigen Presentation 970
 - 46.1.3 Factors Inducing Dendritic Cell Maturation and Migration 971
 - 46.1.3.1 Ischemia/reperfusion Injury 971
 - 46.1.3.2 Links between Innate and Adaptive Immunity during Allograft Rejection 972
- 46.2 Alloantigen Presentation during Graft-versus-host Disease 973
 - 46.2.1 Dual Impact of Alloreactive T Cells during Graft-versus-host Disease 973
 - 46.2.2 Role of Host Dendritic Cells 974
 - 46.2.2.1 Host Dendritic Cells in the Initiation and Effector Phases of Graft-versus-host Disease 974
 - 46.2.2.2 Attempts to Eliminate Host Dendritic Cells 975
 - 46.2.2.3 The Effects of Recipient Conditioning on Dendritic Cell Maturation 975
 - 46.2.2.4 Reconstitution of Dendritic Cell ContentLAQ1L 976
 - 46.2.3 Role of Donor Dendritic Cells 977
 - Acknowledgements 977
 - References 978

47	Dendritic Cells and Transplantation Tolerance	983
	Paul J. Fairchild, Stephen F. Yates and Herman Waldmann	983
47.1	The Expanding World of Transplantation	983
47.2	The Role of Dendritic Cells in Allograft Rejection	985
47.2.1	Direct Presentation of Alloantigen	985
47.2.2	Indirect Presentation of Alloantigen	986
47.2.3	The Semi-direct Pathway of Alloantigen Presentation	987
47.2.4	Pathways of Antigen Presentation during Cell Replacement Therapy	988
47.3	The Role of Dendritic Cells in Self-tolerance	989
47.3.1	A Cell Type with Two Persona	989
47.3.2	Dendritic Cell Subsets Devoted to Tolerance	990
47.3.2.1	Dendritic Cells Expressing CD8 α	990
47.3.2.2	Plasmacytoid Dendritic Cells	991
47.3.2.3	“Regulatory” Dendritic Cells	993
47.3.3	The Maturation Status of Dendritic Cells	994
47.3.3.1	Immature Dendritic Cells have an Enhanced Capacity to be Tolerogenic	994
47.3.3.2	Maturation of Dendritic Cells as a Trigger Point for Immunity	996
47.4	Exploitation of Dendritic Cells for Transplantation Tolerance	997
47.4.1	Central Deletion of Alloreactive T Cells	997
47.4.2	Peripheral Regulation of Alloreactive T Cells	1000
47.4.3	Reinforcing a Tolerogenic Phenotype by Genetic Modification	1001
47.5	Prospects for the Induction of Tolerance via the Indirect Pathway	1002
47.6	Immune Intervention in Cell Replacement Therapy	1005
47.6.1	Generation of Hematopoietic Stem Cells (HSC) for Mixed Chimerism	1005
47.6.2	Generation of Dendritic Cells for Tolerance Induction	1006
	References	1008
48	Dendritic Cells, Immune Regulation and Transplant Tolerance	1017
	<i>Giorgio Raimondi and Angus W. Thomson</i>	
48.1	Introduction	1017
48.2	Dendritic Cells and Initiation of the Rejection Response	1017
48.3	Direct versus Indirect Pathways of Allorecognition	1020
48.4	Dendritic Cells and Tolerance Induction	1021
48.5	Mechanisms underlying Dendritic-cell-induced T-cell Tolerance	1022
48.6	Dendritic Cells and the Control of Organ Transplant Outcome	1026
48.6.1	Dendritic Cell Manipulation for Tolerance Induction: Specific Culture Conditions	1027
48.6.2	Dendritic Cell Manipulation for Tolerance Induction: Pharmacological Manipulation	1027
48.6.3	Dendritic Cell Manipulation for Tolerance Induction: Genetic Engineering	1028

48.6.4	Use of Specific Dendritic Cell Subsets for Tolerance Induction	1029
48.6.5	Dendritic Cell Therapy: Targeting the Indirect Pathway	1031
48.6.6	Dendritic Cells and the Treatment of Chronic Rejection	1033
48.7	Dendritic Cells and Cellular Markers of Transplant Tolerance	1034
48.8	Toward Clinical Use of Dendritic-cell-based Therapies for Tolerance Induction: Critical Considerations and Future Challenges	1035
48.8.1	Dendritic Cell–T Cell Interaction	1035
48.8.2	Dendritic Cells and Treg: a Complex Inter-relationship	1036
48.8.3	Fingerprints of “Tolerogenic” Dendritic Cells	1037
48.8.4	Dendritic Cells at the Crossroads of the Immune System	1037
48.9	Conclusions	1038
	Acknowledgments	1038
	References	1039
XVII	Allergy, Asthma	1047
49	Nickel Presentation to T Cells in Contact Hypersensitivity	1047
	<i>H. U. Weltzien, K. Gernerding and H.-J. Thierse</i>	
49.1	Introduction	1047
49.2	Molecular Basis of Nickel Presentation to Human T Cells	1048
49.2.1	CD4-positive T Cells	1048
49.2.2	CD8-positive T Cells and Non-HLA Restricted Nickel Presentation	1051
49.3	Nickel-Binding Proteins	1051
49.3.1	A Role for Carrier Proteins in Nickel Presentation	1051
49.3.2	Heatshock Proteins as Nickel Binders	1052
49.4	Concluding Remarks	1053
	References	1055
50	Dendritic Cells in Asthma	1059
	<i>Hamida Hammad and Bart N. Lambrecht</i>	
50.1	Introduction	1059
50.2	Asthma as a Th2 Driven Disorder	1059
50.3	Lung Dendritic Cell Subsets	1061
50.4	Function of Lung Dendritic Cells in Primary Immune Responses to Inhaled Antigen and Sensitization to Inhaled Allergen	1062
50.5	Is Tolerance Induction in the Lung a Property of Specialized Dendritic Cell Subsets?	1065
50.6	Accumulation of Mature Dendritic Cells in Ongoing Asthmatic Inflammation	1066
50.7	Direct Proof for a Functional Role for Dendritic Cells in Stimulating Effector Th2 Responses	1068
50.8	Determinants of Dendritic Cell Driven Th2 Responses in Asthma	1069
50.9	Dendritic Cells in Human Asthma	1071
50.10	Conclusion	1072
	References	1073

XVIII Cancer 1081**51 Dendritic Cells in Human Cancer 1081***Casey A. Carlos and Olivera J. Finn*

- 51.1 Introduction 1081
- 51.2 Dendritic Cell Functions that are Important for Effective Immunity against Cancer 1082
- 51.3 Dendritic Cell Recognition of Malignant Changes in Tissues 1083
- 51.4 How Tumors Interfere with Normal Dendritic Cell Function 1084
 - 51.4.1 Inhibition of Maturation and Differentiation 1084
 - 51.4.2 Influence on Migration 1085
 - 51.4.3 Suppression of Function 1086
- 51.5 Summary 1087
- References 1088

Part C Therapeutical Applications of Dendritic Cells 1093**XIX Cancer 1095****52 Dendritic Cell Subsets as Targets and Vectors for Vaccination 1095***Hideki Ueno, Joseph Fay, Jacques Banchereau and A. Karolina Palucka*

- 52.1 Introduction 1095
- 52.2 Cancer Vaccines 1096
- 52.3 Dendritic Cells 1097
 - 52.3.1 Dendritic Cell Subsets 1097
 - 52.3.2 Distinct Dendritic Cell Subsets Induce Distinct Types of Immune Response 1099
 - 52.3.3 Dendritic Cells and Immune Tolerance 1100
- 52.4 Dendritic Cells as Cancer Vaccines 1100
 - 52.4.1 Dendritic Cell Subsets 1100
 - 52.4.2 Dendritic Cell Maturation 1101
 - 52.4.3 Dendritic Cell Migration 1102
 - 52.4.4 Antigen Loading 1103
- 52.5 Regulatory/suppressor Mechanisms 1104
- 52.6 Immunological and Clinical Efficacy 1105
 - 52.6.1 Immunological Efficacy 1105
 - 52.6.2 Clinical Efficacy 1106
- 52.7 Conclusions 1107
- Acknowledgements 1107
- References 1107

- 53 Renal Cell Carcinoma 1117**
Martin Thurnher, Thomas Putz, Andrea Rahm, Hubert Gander, Reinhold Ramoner, Georg Bartsch, Lorenz Hörtl and Claudia Falkensammer
- 53.1 Dendritic Cells and Cancer Immunosurveillance 1117
- 53.2 Renal Cell Carcinoma 1117
- 53.3 Immunotherapy of Renal Cell Carcinoma 1118
- 53.4 Dendritic Cell-based Immunotherapy of Renal Cell Carcinoma 1119
- 53.4.1 The Two-step Culture System 1119
- 53.4.2 Generation of Clinical Grade Dendritic Cells 1119
- 53.4.3 Clinical Trials of Dendritic Cells in Renal Cell Carcinoma Patients 1120
- 53.5 Adjuvant Immunotherapy of Organ Confined Renal Cell Carcinoma after Partial or Radical Nephrectomy 1122
- 53.6 Patient Selection in Future Trials 1123
- 53.7 Adverse Effects – Quality of Life 1123
- 53.8 Concluding Remarks 1124
 Acknowledgements 1124
 References 1124
- XX Antigen Delivery 1129**
- 54 Crosspresentation and Loading of Tumor Antigens for Dendritic Cell Vaccination against Cancer 1129**
Madhav V. Dhodapkar
- 54.1 Approaches to Antigen Loading for Dendritic-cell-mediated Immunotherapy 1129
- 54.2 Importance of Receptor-mediated Uptake to Crosspresentation 1130
- 54.3 Uptake of Dying Cells 1131
- 54.4 Uptake of Immune Complexes and Opsonized Pathogens and Tumor Cells 1131
- 54.5 Uptake of Heat Shock Protein–Peptide Complexes 1132
- 54.6 Exosomes as Sources of Multiple Tumor Antigens 1133
- 54.7 Role of C-type Lectin Receptors 1133
- 54.8 Other Routes of Antigen Entry for Crosspresentation 1133
- 54.9 Processing of the Antigenic Cargo 1134
- 54.10 Nature of the Antigenic Cargo 1134
- 54.11 Regulation of Crosspresentation during Dendritic Cell Maturation 1135
- 54.12 Role of Dendritic Cell Subsets in Crosspresentation 1136
- 54.13 Some Approaches to Improve Antigen Loading of Dendritic Cells for Clinical Vaccination 1136
- 54.14 Concluding Remarks 1137
 References 1138

55	Nucleic Acid Transfer	1143
	<i>Niels Schaft, Jan Dörrie and Dirk M. Nettelbeck</i>	
55.1	General Introduction	1143
55.2	Antigen Delivery to DC by Adenoviral Gene Transfer	1145
55.2.1	Recombinant Adenovirus as Gene Transfer Vector	1146
55.2.2	Adenoviral Gene Transfer into Dendritic Cells in Vitro	1149
55.2.3	Adenoviral Antigen Delivery to DC for Ex Vivo Tumor Vaccination in Mouse Tumor Models	1151
55.2.4	Adenoviral Ag Delivery for HIV/SIV Vaccination in Monkeys	1153
55.3	Antigen Delivery to DC by Transfection of Nucleic Acids	1154
55.3.1	Passive Pulsing	1155
55.3.2	Electroporation	1156
55.3.3	Lipofection	1159
55.4	Concluding Remarks	1160
	References	1161
	Subject Index	1173